Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
Publication/Presentation Date
6-1-2007
Abstract
Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam 2 mg +/- oral aprepitant 125 mg. The hypothesis was that midazolam AUC would not change by more than 2-fold (consistent with no more than weak inhibition) when midazolam + aprepitant was compared with midazolam alone. An AUC geometric mean ratio (midazolam + aprepitant/midazolam) with 90% confidence interval upper bound < or =2.0 (an increase in midazolam felt to be of modest clinical significance in the highly monitored perioperative period) was prespecified. Aprepitant increased intravenous midazolam AUC(0-infinity) 1.47-fold (90% confidence interval, 1.36-1.59), which fell within the prespecified criterion.
Volume
47
Issue
6
First Page
744
Last Page
750
ISSN
0091-2700
Published In/Presented At
Majumdar, A. K., Yan, K. X., Selverian, D. V., Barlas, S., Constanzer, M., Dru, J., McCrea, J. B., Ahmed, T., Frick, G. S., Kraft, W. K., Petty, K. J., & Greenberg, H. E. (2007). Effect of aprepitant on the pharmacokinetics of intravenous midazolam. Journal of clinical pharmacology, 47(6), 744–750. https://doi.org/10.1177/0091270007300807
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
17463213
Department(s)
Administration and Leadership
Document Type
Article